PDF 
Views 
Share
Mitochondria Targeted Derivative of Curcumin for Pancreatic Cancer
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(S 01): S1-S16
DOI: DOI: 10.1055/s-0044-1788227
*Corresponding author: (e-mail: vishakhalikhite@gmail.com).
Abstract
Background: Pancreatic cancer is a rare subgroup of cancers with 5-year survival rate of only 7.3% with very poor prognosis. Therefore, there is a need to devise alternative therapeutic targets. Here we have used mitocurcumin synthesized in our laboratory that targets the mitochondrial population, thereby reducing their survival efficiency.
Methods: Mitocurcumin (MC) is a derivative of curcumin attached to a linker and triphenylphosphonium moiety, which can be selectively targeted to the mitochondria. Its efficiency was validated in vitro using Alamar Blue assay on Miapaca-2 cells. Mitocurcumin and curcumin uptake and their effect on invasion and migration was compared using live cell microscopy.
Results: Using Alamar assay, mitocurcumin was found to be 1,000-fold more potent than curcumin (IC50 of curcumin is 10 µm, whereas IC50 of mitocurcumin is 10 nm). It was also observed that the uptake of mitocurcumin was more than that as compared to curcumin in the mitochondria of pancreatic cancer cells. Invasion and migration studies also showed promising results.
Conclusion: This study provides novel evidence of the therapeutic efficiency of mitocurcumin as a treatment option in pancreatic cancer cell model.
Publication History
Article published online:
08 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
*Corresponding author: (e-mail: vishakhalikhite@gmail.com).
Abstract
Background: Pancreatic cancer is a rare subgroup of cancers with 5-year survival rate of only 7.3% with very poor prognosis. Therefore, there is a need to devise alternative therapeutic targets. Here we have used mitocurcumin synthesized in our laboratory that targets the mitochondrial population, thereby reducing their survival efficiency.
Methods: Mitocurcumin (MC) is a derivative of curcumin attached to a linker and triphenylphosphonium moiety, which can be selectively targeted to the mitochondria. Its efficiency was validated in vitro using Alamar Blue assay on Miapaca-2 cells. Mitocurcumin and curcumin uptake and their effect on invasion and migration was compared using live cell microscopy.
Results: Using Alamar assay, mitocurcumin was found to be 1,000-fold more potent than curcumin (IC50 of curcumin is 10 µm, whereas IC50 of mitocurcumin is 10 nm). It was also observed that the uptake of mitocurcumin was more than that as compared to curcumin in the mitochondria of pancreatic cancer cells. Invasion and migration studies also showed promising results.
Conclusion: This study provides novel evidence of the therapeutic efficiency of mitocurcumin as a treatment option in pancreatic cancer cell model.
No conflict of interest has been declared by the author(s).
Publication History
Article published online:
08 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India